1
1
1
1
2
2
1
1
2012
2001
Company (5)
1 - 5 of 5
Sort by
Patent
Publication NumberEP 1827468 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2005-07-13Publication Date2012-08-22
Patent
Publication NumberUS 20110286998Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2010-11-19Publication Date2011-11-24
Methods are provided for treating HPG axis-positive cancers, preventing or slowing proliferation of cells of HPG axis-positive cancer origin, preventing HPG axis-positive cancers in a patient at risk of contracting such cancers, preventing or inhibiting an upregulation of the cell cycle in HPG axis-positive cancer-derived cells in a patient, and decreasing the level of HPG axis-positive cancer-specific markers in a patient.
Patent
Publication NumberUS 20110195898Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2010-08-30Publication Date2011-08-11
Methods of treating, mitigating, slowing the progression of, or preventing Alzheimer's Disease and Mild Cognitive Impairment (MCI) include administration of gonadotropin-releasing hormone analogs in combination with acetylcholinesterase inhibitors and/or N-methyl-D-aspartate receptor antagonists.
Patent
Publication NumberUS 20100267620Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2010-03-22Publication Date2010-10-21
The present invention relates to a method for slowing, preventing or delaying senescence or treating or preventing a disease associated with senescence by administering a therapeutically effective amount of at least one physiological agent that decreases or regulates the blood level, production, function or activity of LH or FSH, or that decreases or regulates the production or activity of activin, or that increases or regulates the blood level, production, function, or activity of inhibin or…
Patent
Publication NumberUS 6242421Filing StatusIssued PatentAvailabilityUnknownFiling Date1999-06-04Publication Date2001-06-05
A method for treating Alzheimer's disease or preventing or delaying its onset in individuals deemed by competent observation and testing to be susceptible thereto. A non-estrogenic, non-androgenic, non-anabolic agent is dministered to reduce or eliminate blood serum levels of one or both of FSH and LH.
We found 5 documents that match your Search
Patents: 5

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in